The current supply of available Covid-19 vaccines is increasing. There are almost two dozen that have passed clinical trials and have shown correct operation. While there are more than a hundred projects in different stages of development. While in general in biological designed by Johnson & Johnson it has been one of the most questioned because it only requires the application of one dose.
On the one hand, it is a great relief for people with a fear of needles. It also speeds up the vaccination processes because it is not necessary to wait for weeks or months to receive a second inoculation.
Although on the other hand, the problems that Johnson & Johnson has faced are due to the effectiveness of its immunization. At the end of the laboratory tests, it was found that it offers 72 percent protection against serious stages of the disease.
Notable decrease against Variant Delta
Despite the above, a few days ago a study of The New England Journal of Medicine where different vaccines already available against the Delta Variant are compared. In the case of the one designed by Johnson & Johnson, it was one of those that obtained the worst results because its effectiveness decreases to 33 percent when it comes to this mutation of the virus.
With this in mind, the pharmacist is now conducting a phase 2 study to identify whether the application of a second dose improves protection in people. Through a Press release revealed the preliminary results with which he could completely change the indications of his immunization table.
Increased protection when two doses are received
What is mentioned is that if a second booster dose is given between six and eight months after the first there is a nine-fold increase in the antibodies generated.
It is still too early to draw definitive conclusions and you must first conclude the trial. Although if what has been observed up to now remains, then it would cease to be single-dose. In addition, with this, he would join Pfizer with respect to the pharmaceutical companies that support the application of a booster of the biological to provide long-term protection.
For now, it should be remembered that since last May 27, the Federal Commission for the Protection against Sanitary Risks (Cofepris) approved the Johnson & Johnson’s emergency use of the vaccine in Mexico. Thanks to this, it joins AstraZeneca, Cansino, Pfizer, Sinovac, Sputnik V, Covaxin and Moderna as the only eight that have the endorsement.